Michael Joseph Burns, M.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Patient Isolation | 3 | 2016 | 100 | 0.740 |
Why?
|
| Palladium | 2 | 2010 | 67 | 0.640 |
Why?
|
| Communicable Disease Control | 2 | 2016 | 846 | 0.620 |
Why?
|
| Hepatitis A virus | 1 | 2017 | 16 | 0.590 |
Why?
|
| Hepatitis A | 1 | 2017 | 127 | 0.560 |
Why?
|
| Mumps virus | 1 | 2016 | 23 | 0.540 |
Why?
|
| Parotitis | 1 | 2016 | 28 | 0.540 |
Why?
|
| Malingering | 1 | 2016 | 75 | 0.520 |
Why?
|
| Disease Outbreaks | 5 | 2017 | 1747 | 0.520 |
Why?
|
| Mumps | 1 | 2016 | 71 | 0.510 |
Why?
|
| Phosphorus Radioisotopes | 1 | 2015 | 100 | 0.500 |
Why?
|
| Hydrogen | 2 | 2015 | 172 | 0.460 |
Why?
|
| Measles | 1 | 2015 | 181 | 0.420 |
Why?
|
| Ebolavirus | 1 | 2014 | 247 | 0.390 |
Why?
|
| Infectious Disease Transmission, Patient-to-Professional | 1 | 2014 | 250 | 0.380 |
Why?
|
| Pyrones | 1 | 2010 | 35 | 0.360 |
Why?
|
| Phenylpropanolamine | 2 | 2001 | 15 | 0.360 |
Why?
|
| Disease Transmission, Infectious | 1 | 2016 | 561 | 0.350 |
Why?
|
| Methanol | 4 | 2015 | 91 | 0.330 |
Why?
|
| Hemorrhagic Fever, Ebola | 1 | 2014 | 419 | 0.330 |
Why?
|
| Antidotes | 3 | 2005 | 138 | 0.320 |
Why?
|
| Magnetic Resonance Spectroscopy | 3 | 2015 | 3770 | 0.310 |
Why?
|
| Emergency Service, Hospital | 7 | 2016 | 7865 | 0.300 |
Why?
|
| Staphylococcal Infections | 1 | 2016 | 1401 | 0.290 |
Why?
|
| Emergency Medicine | 2 | 2014 | 1198 | 0.280 |
Why?
|
| Carbon | 1 | 2010 | 665 | 0.280 |
Why?
|
| Alcohol-Induced Disorders, Nervous System | 1 | 2005 | 13 | 0.250 |
Why?
|
| Nanotechnology | 3 | 2015 | 713 | 0.240 |
Why?
|
| Pyrazoles | 4 | 2005 | 2010 | 0.230 |
Why?
|
| Pregnancy Complications, Infectious | 1 | 2016 | 2150 | 0.230 |
Why?
|
| Electrochemical Techniques | 2 | 2015 | 93 | 0.220 |
Why?
|
| Solvents | 4 | 2018 | 294 | 0.210 |
Why?
|
| Health Personnel | 1 | 2016 | 3337 | 0.200 |
Why?
|
| Sepsis | 1 | 2016 | 2585 | 0.200 |
Why?
|
| Opioid-Related Disorders | 1 | 2016 | 2164 | 0.190 |
Why?
|
| Liquid Ventilation | 1 | 2001 | 7 | 0.190 |
Why?
|
| Multipotent Stem Cells | 1 | 2003 | 200 | 0.190 |
Why?
|
| Phentolamine | 1 | 2001 | 102 | 0.190 |
Why?
|
| Alcohol Dehydrogenase | 2 | 2000 | 113 | 0.190 |
Why?
|
| Rewarming | 1 | 2001 | 64 | 0.180 |
Why?
|
| Adrenergic alpha-Antagonists | 1 | 2001 | 174 | 0.180 |
Why?
|
| Catalysis | 3 | 2018 | 763 | 0.180 |
Why?
|
| Physostigmine | 1 | 2000 | 50 | 0.180 |
Why?
|
| Adrenergic alpha-Agonists | 1 | 2001 | 177 | 0.170 |
Why?
|
| Nasal Decongestants | 1 | 2000 | 29 | 0.170 |
Why?
|
| Sympathomimetics | 1 | 2000 | 57 | 0.170 |
Why?
|
| Kerosene | 1 | 1999 | 15 | 0.160 |
Why?
|
| Cholinergic Antagonists | 1 | 2000 | 167 | 0.160 |
Why?
|
| Hypothermia | 1 | 2001 | 188 | 0.160 |
Why?
|
| World Health Organization | 2 | 2016 | 1321 | 0.160 |
Why?
|
| Boronic Acids | 3 | 2007 | 915 | 0.160 |
Why?
|
| Cholinesterase Inhibitors | 1 | 2000 | 241 | 0.150 |
Why?
|
| Iridium | 1 | 2018 | 30 | 0.150 |
Why?
|
| Ventricular Fibrillation | 1 | 2001 | 537 | 0.150 |
Why?
|
| Poisoning | 4 | 2001 | 252 | 0.150 |
Why?
|
| Hydrobromic Acid | 1 | 1997 | 1 | 0.140 |
Why?
|
| Toxicity Tests | 1 | 2018 | 115 | 0.140 |
Why?
|
| Bromine | 1 | 1997 | 23 | 0.140 |
Why?
|
| Stem Cell Transplantation | 2 | 2003 | 1600 | 0.140 |
Why?
|
| Coordination Complexes | 1 | 2018 | 73 | 0.140 |
Why?
|
| Fluorocarbons | 2 | 2001 | 492 | 0.140 |
Why?
|
| Echinocandins | 1 | 2016 | 53 | 0.130 |
Why?
|
| Lipopeptides | 1 | 2016 | 70 | 0.130 |
Why?
|
| Fluconazole | 1 | 2016 | 156 | 0.130 |
Why?
|
| Measles-Mumps-Rubella Vaccine | 1 | 2016 | 71 | 0.130 |
Why?
|
| Conductometry | 1 | 2015 | 10 | 0.130 |
Why?
|
| Disinfectants | 1 | 1997 | 129 | 0.130 |
Why?
|
| Microscopy, Electron, Scanning | 2 | 2014 | 944 | 0.130 |
Why?
|
| Microscopy, Scanning Probe | 1 | 2014 | 6 | 0.120 |
Why?
|
| Optical Devices | 1 | 2015 | 35 | 0.120 |
Why?
|
| Ciprofloxacin | 1 | 2016 | 312 | 0.120 |
Why?
|
| Disease Notification | 1 | 2015 | 95 | 0.120 |
Why?
|
| Solutions | 1 | 2015 | 410 | 0.120 |
Why?
|
| Protective Devices | 1 | 2014 | 72 | 0.110 |
Why?
|
| Microelectrodes | 1 | 2015 | 306 | 0.110 |
Why?
|
| Esters | 1 | 2015 | 210 | 0.110 |
Why?
|
| Benzodiazepines | 1 | 2000 | 1134 | 0.110 |
Why?
|
| Carbon Radioisotopes | 1 | 2015 | 561 | 0.110 |
Why?
|
| Public Health | 2 | 2017 | 2672 | 0.110 |
Why?
|
| Surface Plasmon Resonance | 1 | 2014 | 268 | 0.110 |
Why?
|
| Molecular Structure | 2 | 2015 | 1875 | 0.110 |
Why?
|
| Molecular Conformation | 2 | 2014 | 543 | 0.110 |
Why?
|
| Immunotherapy, Adoptive | 1 | 2003 | 1468 | 0.100 |
Why?
|
| Cholera Toxin | 1 | 2015 | 559 | 0.100 |
Why?
|
| Scattering, Radiation | 1 | 2014 | 490 | 0.100 |
Why?
|
| Klebsiella Infections | 1 | 1993 | 144 | 0.100 |
Why?
|
| Chorionic Villi Sampling | 1 | 2011 | 35 | 0.100 |
Why?
|
| Adrenergic beta-Antagonists | 1 | 1997 | 1241 | 0.100 |
Why?
|
| Antifungal Agents | 1 | 2016 | 752 | 0.090 |
Why?
|
| Klebsiella pneumoniae | 1 | 1993 | 249 | 0.090 |
Why?
|
| Wounds, Penetrating | 1 | 1993 | 314 | 0.090 |
Why?
|
| Gold | 1 | 2014 | 482 | 0.090 |
Why?
|
| Pyrazines | 2 | 2007 | 1202 | 0.090 |
Why?
|
| Materials Testing | 1 | 2014 | 865 | 0.090 |
Why?
|
| Travel | 1 | 2016 | 796 | 0.090 |
Why?
|
| Arthritis, Infectious | 1 | 1993 | 347 | 0.080 |
Why?
|
| Stem Cells | 1 | 2003 | 3517 | 0.080 |
Why?
|
| Nanostructures | 1 | 2015 | 551 | 0.080 |
Why?
|
| Stereoisomerism | 1 | 2010 | 611 | 0.080 |
Why?
|
| Protons | 1 | 2015 | 1111 | 0.080 |
Why?
|
| Organometallic Compounds | 1 | 2013 | 647 | 0.080 |
Why?
|
| Brain Neoplasms | 4 | 2003 | 9025 | 0.080 |
Why?
|
| Myocardial Infarction | 2 | 2001 | 11476 | 0.080 |
Why?
|
| Pseudomonas Infections | 1 | 1993 | 621 | 0.080 |
Why?
|
| Aspartate Aminotransferases | 1 | 2010 | 411 | 0.080 |
Why?
|
| Infectious Disease Transmission, Vertical | 1 | 2016 | 1351 | 0.080 |
Why?
|
| Safety Management | 1 | 2014 | 761 | 0.080 |
Why?
|
| Knee Injuries | 1 | 1993 | 488 | 0.080 |
Why?
|
| Fever | 1 | 2016 | 1618 | 0.080 |
Why?
|
| Heart Ventricles | 1 | 2001 | 3813 | 0.080 |
Why?
|
| Drug Interactions | 2 | 2005 | 1417 | 0.080 |
Why?
|
| Light | 1 | 2014 | 1348 | 0.080 |
Why?
|
| Disaster Planning | 1 | 2014 | 557 | 0.080 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2015 | 3803 | 0.070 |
Why?
|
| Practice Guidelines as Topic | 2 | 2016 | 7400 | 0.070 |
Why?
|
| Alanine Transaminase | 1 | 2010 | 602 | 0.070 |
Why?
|
| Antipsychotic Agents | 1 | 2001 | 3064 | 0.070 |
Why?
|
| Models, Molecular | 3 | 2014 | 5406 | 0.070 |
Why?
|
| Analgesics, Non-Narcotic | 1 | 2010 | 370 | 0.070 |
Why?
|
| Alkaline Phosphatase | 2 | 2007 | 859 | 0.070 |
Why?
|
| Enzyme Inhibitors | 1 | 1997 | 3702 | 0.070 |
Why?
|
| Lung Diseases | 1 | 1997 | 1910 | 0.070 |
Why?
|
| Substrate Specificity | 1 | 2010 | 1768 | 0.070 |
Why?
|
| Phantoms, Imaging | 1 | 2015 | 2513 | 0.070 |
Why?
|
| Acetaminophen | 1 | 2010 | 555 | 0.070 |
Why?
|
| Spinal Puncture | 1 | 2008 | 282 | 0.070 |
Why?
|
| Fetal Diseases | 1 | 2011 | 912 | 0.070 |
Why?
|
| Meningitis, Bacterial | 1 | 2008 | 222 | 0.070 |
Why?
|
| Ethanol | 3 | 2014 | 1322 | 0.060 |
Why?
|
| Rats, Wistar | 2 | 2001 | 1848 | 0.060 |
Why?
|
| Chromosomes, Human, Pair 4 | 1 | 2007 | 375 | 0.060 |
Why?
|
| Decision Support Techniques | 1 | 2016 | 2004 | 0.060 |
Why?
|
| Humans | 30 | 2018 | 761208 | 0.060 |
Why?
|
| Guideline Adherence | 1 | 2016 | 2220 | 0.060 |
Why?
|
| Population Surveillance | 1 | 2016 | 2598 | 0.060 |
Why?
|
| Medicine, Ayurvedic | 1 | 2004 | 37 | 0.060 |
Why?
|
| Knee Joint | 1 | 1993 | 1678 | 0.060 |
Why?
|
| Hypoglycemic Agents | 1 | 1997 | 3089 | 0.060 |
Why?
|
| Prenatal Diagnosis | 1 | 2011 | 1267 | 0.060 |
Why?
|
| Plant Preparations | 1 | 2004 | 94 | 0.060 |
Why?
|
| Chromosome Disorders | 1 | 2007 | 497 | 0.060 |
Why?
|
| Metals, Heavy | 1 | 2004 | 148 | 0.050 |
Why?
|
| Neurons | 1 | 2003 | 9428 | 0.050 |
Why?
|
| Diagnosis, Differential | 2 | 2016 | 12976 | 0.050 |
Why?
|
| Insulin | 1 | 1997 | 6588 | 0.050 |
Why?
|
| Hemolysin Proteins | 1 | 2003 | 113 | 0.050 |
Why?
|
| Genes, erbB-1 | 1 | 2003 | 162 | 0.050 |
Why?
|
| Chromosome Deletion | 1 | 2007 | 1386 | 0.050 |
Why?
|
| Schizophrenia | 1 | 2001 | 6930 | 0.050 |
Why?
|
| Protease Inhibitors | 1 | 2005 | 752 | 0.050 |
Why?
|
| 4-Butyrolactone | 1 | 2001 | 61 | 0.050 |
Why?
|
| Physical Stimulation | 1 | 2003 | 517 | 0.050 |
Why?
|
| Pentobarbital | 1 | 2001 | 153 | 0.050 |
Why?
|
| Oligodendroglioma | 1 | 2003 | 278 | 0.050 |
Why?
|
| Electromagnetic Fields | 1 | 2003 | 289 | 0.050 |
Why?
|
| Psychoses, Substance-Induced | 1 | 2001 | 99 | 0.050 |
Why?
|
| Injections, Intravenous | 2 | 2000 | 1376 | 0.050 |
Why?
|
| Lipid Bilayers | 1 | 2003 | 379 | 0.050 |
Why?
|
| Withholding Treatment | 1 | 2005 | 616 | 0.050 |
Why?
|
| Ethylene Glycol | 1 | 2000 | 31 | 0.040 |
Why?
|
| Telomere | 1 | 2007 | 939 | 0.040 |
Why?
|
| Injections, Intraperitoneal | 1 | 2001 | 413 | 0.040 |
Why?
|
| Analgesics, Opioid | 1 | 2016 | 3805 | 0.040 |
Why?
|
| Akathisia, Drug-Induced | 1 | 2000 | 67 | 0.040 |
Why?
|
| Medical Errors | 1 | 2008 | 1263 | 0.040 |
Why?
|
| Stereotaxic Techniques | 1 | 2002 | 555 | 0.040 |
Why?
|
| Therapeutic Irrigation | 1 | 2001 | 293 | 0.040 |
Why?
|
| Alcoholic Intoxication | 1 | 2000 | 174 | 0.040 |
Why?
|
| Risk Factors | 3 | 2017 | 74239 | 0.040 |
Why?
|
| Disease Models, Animal | 4 | 2005 | 18220 | 0.040 |
Why?
|
| Autonomic Nervous System Diseases | 1 | 2001 | 268 | 0.040 |
Why?
|
| United States | 3 | 2017 | 72339 | 0.040 |
Why?
|
| Injections, Intramuscular | 1 | 2000 | 555 | 0.040 |
Why?
|
| Multiple Myeloma | 2 | 2007 | 5145 | 0.040 |
Why?
|
| Nicotinic Acids | 1 | 2018 | 31 | 0.040 |
Why?
|
| Ion Channels | 1 | 2003 | 1038 | 0.040 |
Why?
|
| Calcium Gluconate | 1 | 1997 | 22 | 0.040 |
Why?
|
| Hydrofluoric Acid | 1 | 1997 | 13 | 0.040 |
Why?
|
| Anti-Bacterial Agents | 1 | 2016 | 7407 | 0.040 |
Why?
|
| Body Temperature | 1 | 2001 | 780 | 0.040 |
Why?
|
| Nerve Regeneration | 1 | 2003 | 796 | 0.040 |
Why?
|
| Baths | 1 | 1997 | 53 | 0.030 |
Why?
|
| Substance Withdrawal Syndrome | 1 | 2001 | 624 | 0.030 |
Why?
|
| Burns, Chemical | 1 | 1997 | 123 | 0.030 |
Why?
|
| Pregnancy | 2 | 2016 | 29893 | 0.030 |
Why?
|
| Female | 13 | 2016 | 392544 | 0.030 |
Why?
|
| Animals | 8 | 2005 | 168079 | 0.030 |
Why?
|
| Infusions, Intravenous | 2 | 1997 | 2217 | 0.030 |
Why?
|
| Administration, Inhalation | 1 | 1999 | 1159 | 0.030 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 2 | 2007 | 11733 | 0.030 |
Why?
|
| Glucagon | 1 | 1997 | 531 | 0.030 |
Why?
|
| Emergencies | 2 | 2000 | 1217 | 0.030 |
Why?
|
| Retinal Diseases | 1 | 2001 | 705 | 0.030 |
Why?
|
| Isomerism | 1 | 2014 | 197 | 0.030 |
Why?
|
| Young Adult | 3 | 2016 | 59221 | 0.030 |
Why?
|
| Rats | 2 | 2001 | 23704 | 0.030 |
Why?
|
| Vision Disorders | 1 | 2001 | 1088 | 0.030 |
Why?
|
| Acute Disease | 2 | 2010 | 7226 | 0.030 |
Why?
|
| Longevity | 1 | 2001 | 1063 | 0.030 |
Why?
|
| Equipment Failure Analysis | 1 | 2015 | 846 | 0.030 |
Why?
|
| Central Nervous System | 1 | 2000 | 1333 | 0.030 |
Why?
|
| Dogs | 1 | 1997 | 3832 | 0.030 |
Why?
|
| Human T-lymphotropic virus 2 | 1 | 1992 | 10 | 0.030 |
Why?
|
| Analysis of Variance | 1 | 2001 | 6223 | 0.020 |
Why?
|
| Male | 11 | 2016 | 360693 | 0.020 |
Why?
|
| Administration, Oral | 1 | 2000 | 4015 | 0.020 |
Why?
|
| Isotope Labeling | 1 | 2013 | 393 | 0.020 |
Why?
|
| Magnetic Resonance Imaging | 2 | 2014 | 36415 | 0.020 |
Why?
|
| Human T-lymphotropic virus 1 | 1 | 1992 | 142 | 0.020 |
Why?
|
| Adult | 11 | 2011 | 221119 | 0.020 |
Why?
|
| Osteoblasts | 2 | 2007 | 1144 | 0.020 |
Why?
|
| Intubation, Intratracheal | 1 | 1999 | 1331 | 0.020 |
Why?
|
| Swine | 1 | 2001 | 5909 | 0.020 |
Why?
|
| Hemodynamics | 1 | 2001 | 4165 | 0.020 |
Why?
|
| Biocompatible Materials | 1 | 2018 | 1683 | 0.020 |
Why?
|
| DNA | 1 | 2003 | 7189 | 0.020 |
Why?
|
| Dexamethasone | 2 | 2007 | 1945 | 0.020 |
Why?
|
| Reproducibility of Results | 2 | 2015 | 20119 | 0.020 |
Why?
|
| Maternal Age | 1 | 2011 | 809 | 0.020 |
Why?
|
| Hepatitis B virus | 1 | 1992 | 527 | 0.020 |
Why?
|
| Crystallography, X-Ray | 1 | 2013 | 1978 | 0.020 |
Why?
|
| Delirium | 1 | 2000 | 1668 | 0.020 |
Why?
|
| Aneuploidy | 1 | 2011 | 555 | 0.020 |
Why?
|
| Cell Survival | 1 | 2018 | 5778 | 0.020 |
Why?
|
| Respiration, Artificial | 1 | 1999 | 2631 | 0.020 |
Why?
|
| Water | 1 | 2014 | 1410 | 0.020 |
Why?
|
| Equipment Design | 1 | 2015 | 3510 | 0.020 |
Why?
|
| Glioma | 1 | 2002 | 3452 | 0.020 |
Why?
|
| Medical Audit | 1 | 2008 | 452 | 0.020 |
Why?
|
| Menorrhagia | 1 | 2007 | 59 | 0.020 |
Why?
|
| beta 2-Microglobulin | 1 | 2007 | 329 | 0.020 |
Why?
|
| HIV Seropositivity | 1 | 1992 | 957 | 0.020 |
Why?
|
| Electrocardiography | 1 | 2000 | 6387 | 0.020 |
Why?
|
| Hospitals, University | 1 | 2008 | 565 | 0.020 |
Why?
|
| Genitalia, Female | 1 | 2007 | 146 | 0.020 |
Why?
|
| History, 21st Century | 1 | 2011 | 1567 | 0.020 |
Why?
|
| Cerebrospinal Fluid | 1 | 2008 | 544 | 0.020 |
Why?
|
| Sensitivity and Specificity | 2 | 2015 | 14675 | 0.020 |
Why?
|
| Mercury Poisoning | 1 | 2004 | 32 | 0.020 |
Why?
|
| Asia, Southeastern | 1 | 2004 | 114 | 0.020 |
Why?
|
| Arsenic Poisoning | 1 | 2004 | 55 | 0.010 |
Why?
|
| Spectrometry, X-Ray Emission | 1 | 2004 | 143 | 0.010 |
Why?
|
| Craniofacial Abnormalities | 1 | 2007 | 319 | 0.010 |
Why?
|
| Cell Count | 1 | 2008 | 1831 | 0.010 |
Why?
|
| Retrospective Studies | 4 | 2011 | 80674 | 0.010 |
Why?
|
| Specimen Handling | 1 | 2008 | 702 | 0.010 |
Why?
|
| Oncogene Proteins v-erbB | 1 | 2003 | 17 | 0.010 |
Why?
|
| Mice | 3 | 2005 | 81326 | 0.010 |
Why?
|
| Legislation, Drug | 1 | 2004 | 214 | 0.010 |
Why?
|
| Chromosomes, Mammalian | 1 | 2003 | 147 | 0.010 |
Why?
|
| S100 Proteins | 1 | 2003 | 216 | 0.010 |
Why?
|
| Porosity | 1 | 2003 | 348 | 0.010 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2007 | 10756 | 0.010 |
Why?
|
| Mercury | 1 | 2004 | 289 | 0.010 |
Why?
|
| Mice, Inbred DBA | 1 | 2003 | 623 | 0.010 |
Why?
|
| Electroporation | 1 | 2003 | 233 | 0.010 |
Why?
|
| Lead Poisoning | 1 | 2004 | 323 | 0.010 |
Why?
|
| Arsenic | 1 | 2004 | 361 | 0.010 |
Why?
|
| Chi-Square Distribution | 1 | 2007 | 3418 | 0.010 |
Why?
|
| Cell Line, Tumor | 1 | 2018 | 16952 | 0.010 |
Why?
|
| Buffers | 1 | 2001 | 143 | 0.010 |
Why?
|
| Permeability | 1 | 2003 | 721 | 0.010 |
Why?
|
| Ion Channel Gating | 1 | 2003 | 428 | 0.010 |
Why?
|
| Ferrosoferric Oxide | 1 | 2002 | 348 | 0.010 |
Why?
|
| Sodium Bicarbonate | 1 | 2001 | 60 | 0.010 |
Why?
|
| Genes, p53 | 1 | 2003 | 713 | 0.010 |
Why?
|
| Oxides | 1 | 2002 | 401 | 0.010 |
Why?
|
| Magnetite Nanoparticles | 1 | 2002 | 316 | 0.010 |
Why?
|
| Epidermal Growth Factor | 1 | 2003 | 699 | 0.010 |
Why?
|
| Thalidomide | 1 | 2005 | 885 | 0.010 |
Why?
|
| Dextrans | 1 | 2002 | 574 | 0.010 |
Why?
|
| Nerve Growth Factors | 1 | 2003 | 564 | 0.010 |
Why?
|
| Mice, Transgenic | 2 | 2003 | 9520 | 0.010 |
Why?
|
| Central Nervous System Depressants | 1 | 2001 | 164 | 0.010 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p16 | 1 | 2003 | 697 | 0.010 |
Why?
|
| Commerce | 1 | 2004 | 608 | 0.010 |
Why?
|
| Motion | 1 | 2003 | 779 | 0.010 |
Why?
|
| Feedback | 1 | 2003 | 790 | 0.010 |
Why?
|
| Wounds and Injuries | 1 | 1992 | 2493 | 0.010 |
Why?
|
| Antineoplastic Agents, Hormonal | 1 | 2007 | 1520 | 0.010 |
Why?
|
| Adolescent | 4 | 2011 | 88298 | 0.010 |
Why?
|
| Chemokines | 1 | 2003 | 956 | 0.010 |
Why?
|
| Lead | 1 | 2004 | 879 | 0.010 |
Why?
|
| Gadolinium DTPA | 1 | 2002 | 823 | 0.010 |
Why?
|
| Parathyroid Hormone | 1 | 2005 | 1803 | 0.010 |
Why?
|
| Creatine | 1 | 2000 | 427 | 0.010 |
Why?
|
| Kidney Function Tests | 1 | 2000 | 680 | 0.010 |
Why?
|
| Developmental Disabilities | 1 | 2007 | 1510 | 0.010 |
Why?
|
| Stress, Mechanical | 1 | 2003 | 1674 | 0.010 |
Why?
|
| Child | 3 | 2008 | 80152 | 0.010 |
Why?
|
| Infant, Newborn | 2 | 2008 | 26199 | 0.010 |
Why?
|
| Tourniquets | 1 | 1997 | 107 | 0.010 |
Why?
|
| Chromosome Aberrations | 1 | 2003 | 1767 | 0.010 |
Why?
|
| Middle Aged | 5 | 2011 | 220853 | 0.010 |
Why?
|
| Mass Screening | 1 | 2011 | 5426 | 0.010 |
Why?
|
| Arousal | 1 | 2001 | 1171 | 0.010 |
Why?
|
| Infant | 2 | 2008 | 36169 | 0.010 |
Why?
|
| Tumor Cells, Cultured | 1 | 2003 | 6124 | 0.010 |
Why?
|
| Forearm | 1 | 1997 | 427 | 0.010 |
Why?
|
| Probability | 1 | 2000 | 2478 | 0.010 |
Why?
|
| Models, Neurological | 1 | 2003 | 1769 | 0.010 |
Why?
|
| Treatment Outcome | 4 | 2005 | 64681 | 0.010 |
Why?
|
| Child, Preschool | 2 | 2008 | 42224 | 0.010 |
Why?
|
| Prevalence | 1 | 2011 | 15721 | 0.010 |
Why?
|
| Fingers | 1 | 1997 | 506 | 0.010 |
Why?
|
| Genetic Testing | 1 | 2007 | 3537 | 0.010 |
Why?
|
| Iron | 1 | 2002 | 1790 | 0.010 |
Why?
|
| Logistic Models | 1 | 2007 | 13249 | 0.010 |
Why?
|
| Risk | 1 | 2004 | 9616 | 0.010 |
Why?
|
| Clinical Competence | 1 | 2008 | 4788 | 0.010 |
Why?
|
| Boston | 1 | 2004 | 9327 | 0.010 |
Why?
|
| Promoter Regions, Genetic | 1 | 2003 | 5773 | 0.010 |
Why?
|
| Clinical Trials as Topic | 1 | 2007 | 8003 | 0.010 |
Why?
|
| Predictive Value of Tests | 1 | 2007 | 15308 | 0.010 |
Why?
|
| Cell Movement | 1 | 2003 | 5195 | 0.010 |
Why?
|
| Hepatitis B Surface Antigens | 1 | 1992 | 294 | 0.010 |
Why?
|
| Renal Dialysis | 1 | 2000 | 1796 | 0.010 |
Why?
|
| Disease Progression | 1 | 2007 | 13511 | 0.010 |
Why?
|
| Biopsy | 1 | 2002 | 6781 | 0.010 |
Why?
|
| Phenotype | 1 | 2007 | 16575 | 0.000 |
Why?
|
| Contrast Media | 1 | 2002 | 5311 | 0.000 |
Why?
|
| Cohort Studies | 1 | 2011 | 41496 | 0.000 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2005 | 10218 | 0.000 |
Why?
|
| Cell Differentiation | 1 | 2005 | 11509 | 0.000 |
Why?
|
| California | 1 | 1992 | 1431 | 0.000 |
Why?
|
| Time Factors | 1 | 2007 | 39957 | 0.000 |
Why?
|
| Gene Expression Regulation | 1 | 2003 | 11856 | 0.000 |
Why?
|
| Mice, Inbred C57BL | 1 | 2003 | 22127 | 0.000 |
Why?
|
| Pain | 1 | 1997 | 5072 | 0.000 |
Why?
|
| Aged | 2 | 2008 | 169288 | 0.000 |
Why?
|
| Brain | 1 | 2007 | 27092 | 0.000 |
Why?
|
| Mutation | 1 | 2003 | 30002 | 0.000 |
Why?
|
| Prospective Studies | 1 | 1992 | 54435 | 0.000 |
Why?
|